GLP-1 Family & Incretin Mimetics: Peptide Class Overview

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are synthetic peptides that mimic or potentiate the action of endogenous GLP-1, a 30-amino-acid incretin hormone secreted by L-cells of the distal small intestine in response to nutrient ingestion. Endogenous GLP-1 has a plasma half-life of roughly 2 minutes because dipeptidyl peptidase-4 (DPP-4) cleaves it rapidly at the N-terminus (PMID: 8263271). Pharmacological GLP-1 RAs are engineered to resist DPP-4 cleavage, extending the hormonal signal from minutes to days or weeks.

The class has expanded from single-receptor GLP-1 agonists into dual- and triple-receptor co-agonists that add GIP (glucose-dependent insulinotropic polypeptide) receptor activity, glucagon receptor activity, or both. This receptor-stacking strategy has produced progressively larger reductions in body weight and glycemic indices across successive compounds.

This page provides a high-level orientation to the class. Detailed mechanistic, pharmacokinetic, and evidence profiles are on each compound’s hub page.

All compounds in this class share a single proximal mechanism: sustained activation of the GLP-1 receptor (GLP-1R), a class B Gs-coupled GPCR expressed on pancreatic beta cells, the hypothalamus, the brainstem, the vagus nerve, the heart, and the kidney. Downstream of GLP-1R activation:

Pancreatic beta cells increase glucose-dependent insulin secretion and suppress glucagon from alpha cells, lowering post-prandial glucose without driving fasting hypoglycemia (PMID: 8263271).
Hypothalamic and brainstem circuits reduce appetite and food intake through effects on the arcuate nucleus and the area postrema (PMID: 30006227).
Gastric emptying slows, blunting post-prandial glucose excursions.
Cardiovascular effects include modest reductions in heart rate and blood pressure, plus direct cardioprotective signaling through cAMP in cardiomyocytes.

The unifying clinical outputs are glycemic control, appetite reduction, and body weight loss. The magnitude of these effects has increased substantially as receptor polyagonism has been added to the core GLP-1 scaffold.

None of the compounds on this page are presented with dosing guidance. This page is for research and educational purposes only.

Brief History of the Class

1986. Glucagon-like peptide-1 was identified as a post-translational cleavage product of proglucagon in gut L-cells. Early studies established that it potentiated glucose-stimulated insulin secretion in a strictly glucose-dependent manner, distinguishing it from sulfonylureas and other secretagogues of that era (PMID: 3536982).

1992. Exendin-4, a 39-amino-acid peptide isolated from the saliva of Heloderma suspectum (Gila monster), was found to be a potent GLP-1R agonist with DPP-4 resistance. Its 53% sequence homology to human GLP-1 and its resistance to rapid degradation made it the template for the first clinical GLP-1 RAs (PMID: 1397645).

2005. The FDA approved exenatide (Byetta, Amylin/Eli Lilly), a synthetic exendin-4 analog administered twice daily, for type 2 diabetes. This was the first approved GLP-1 RA and established proof of concept for the therapeutic class (FDA NDA 021773).

2010. Liraglutide (Victoza, Novo Nordisk), a once-daily GLP-1 analog with 97% homology to human GLP-1 and a C-16 fatty acid chain enabling albumin binding, was approved for type 2 diabetes in the US. Liraglutide’s extended half-life (~13 hours) was the first major durability advance over exenatide (FDA NDA 022341).

2012-2016. The LEADER cardiovascular outcomes trial enrolled over 9,000 high-risk type 2 diabetes patients on liraglutide, providing the first large-scale MACE (major adverse cardiovascular event) endpoint data for a GLP-1 RA. Results published in 2016 showed a statistically significant reduction in the composite MACE endpoint (PMID: 27295427). This shifted the class from a glucose-lowering tool to a cardiovascular risk-reduction agent.

2017. Semaglutide (Ozempic, Novo Nordisk), a GLP-1 analog with a C-18 fatty diacid chain and two amino acid substitutions for DPP-4 resistance, received FDA approval for type 2 diabetes. Its once-weekly dosing schedule and superior glycemic efficacy relative to liraglutide drove rapid adoption (FDA NDA 209637). The SUSTAIN-6 trial reported a 26% reduction in MACE versus placebo (PMID: 28095528).

2021. Once-weekly subcutaneous semaglutide 2.4 mg (Wegovy, Novo Nordisk) was approved for chronic weight management, based on the STEP 1 trial showing a mean 14.9% reduction in body weight versus 2.4% for placebo in adults with obesity (NCT03548935, PMID: 33567185). This approval formally established the class as an obesity pharmacotherapy, not only a diabetes treatment.

2022. Tirzepatide (Mounjaro, Eli Lilly) received FDA approval for type 2 diabetes. Tirzepatide is a dual GLP-1R / GIP-R co-agonist, the first approved compound to combine both incretin receptors in a single molecule. The SURPASS-2 trial demonstrated HbA1c reductions and weight loss exceeding those seen with semaglutide in a head-to-head comparison (NCT03987919, PMID: 34170647).

2023. Tirzepatide (Zepbound) was approved for chronic weight management, supported by the SURMOUNT-1 trial showing a mean 20.9% body weight reduction versus 3.1% for placebo (NCT04184622, PMID: 37610352). This exceeded the weight reduction achieved with semaglutide in its pivotal obesity trial.

2023-present. Retatrutide, a triple GLP-1R / GIP-R / glucagon receptor (GCGR) co-agonist developed by Eli Lilly, completed Phase II trials (NCT04881760). Dose-escalation data presented at ADA 2023 showed mean body weight reductions of up to 24.2% at 48 weeks (PMID: 37387074), the largest pharmacological weight loss reported in a randomized controlled trial at that time. Phase III registration trials are ongoing.

Shared Pathway: Incretin Receptor Pharmacology

The diagram below maps the receptor targets of each compound and their convergence on metabolic outputs.

flowchart TD
    GLP1["Endogenous GLP-1\n(secreted by gut L-cells\nafter nutrient ingestion)"] --> DPP4["DPP-4 cleavage\nt½ ~2 min"]
    DPP4 --> Inactivated["Inactive GLP-1 fragment"]

    SEM["Semaglutide\n(GLP-1R agonist)"] --> GLP1R
    TIR["Tirzepatide\n(GLP-1R + GIP-R co-agonist)"] --> GLP1R
    TIR --> GIPR["GIP Receptor\n(Gs-coupled GPCR)\npancreas, adipose, brain"]
    RET["Retatrutide\n(GLP-1R + GIP-R + GCGR\ntriple agonist)"] --> GLP1R
    RET --> GIPR
    RET --> GCGR["Glucagon Receptor\n(Gs-coupled GPCR)\nliver, adipose, heart"]

    GLP1R["GLP-1 Receptor\n(Class B GPCR)\npancreas, brain, heart,\nkidney, vagus nerve"] --> cAMP["↑ cAMP\nPKA activation"]

    cAMP --> Insulin["Glucose-dependent\ninsulin secretion\n(beta cells)"]
    cAMP --> Glucagon["Glucagon suppression\n(alpha cells)"]
    cAMP --> Appetite["Hypothalamic / brainstem\nsatiety signaling\n↓ food intake"]
    cAMP --> Gastric["Slowed gastric emptying\n↓ post-prandial glucose"]
    cAMP --> Cardio["Cardiomyocyte protection\ncAMP-mediated"]

    GIPR --> GIP_out["↑ insulin secretion\nfat cell lipolysis\nbone homeostasis\namplifies GLP-1R effects"]
    GCGR --> GCGR_out["↑ hepatic glucose output\n↑ lipolysis and fatty acid\noxidation in adipose\n↑ energy expenditure"]

    Insulin --> Glycemia["Glycemic control\n↓ HbA1c"]
    Glucagon --> Glycemia
    Gastric --> Glycemia
    Appetite --> Weight["Body weight reduction"]
    GIP_out --> Weight
    GCGR_out --> Weight
    Glycemia --> CV["Cardiovascular\nrisk reduction"]
    Weight --> CV

Compound Comparison Table

Compound	Receptor Targets	Half-life	FDA Status	Peak Weight Reduction (RCT)	Primary Evidence
Semaglutide	GLP-1R	~1 week (SC)	Approved: T2D (NDA 209637), obesity (NDA 214874)	~14.9% (STEP 1; NCT03548935)	Phase III; SUSTAIN-6 MACE data
Tirzepatide	GLP-1R + GIP-R	~5 days	Approved: T2D (NDA 215866), obesity (NDA 217806)	~20.9% (SURMOUNT-1; NCT04184622)	Phase III; SURPASS series; SURMOUNT series
Retatrutide	GLP-1R + GIP-R + GCGR	~6 days (est.)	Phase III (no FDA approval)	~24.2% (Phase II; NCT04881760)	Phase II; PMID: 37387074

Key Differentiators Within the Class

Receptor valency. The most structurally consequential difference among these three compounds is the number of incretin receptors engaged. Semaglutide is a monoagonist; tirzepatide adds GIP-R co-agonism; retatrutide adds glucagon receptor (GCGR) activity on top of both. Each additional receptor contributes distinct metabolic effects. GIP-R agonism augments insulin secretion in a glucose-dependent manner and appears to enhance the central appetite suppression of GLP-1R activation through additive hypothalamic signaling (PMID: 34170647). GCGR agonism drives hepatic glucose output and lipolysis, raising theoretical concerns about counteracting glycemic effects, but in the context of a strong GLP-1R / GIP-R background, the net result has been greater energy expenditure and larger weight reductions without clinically significant hyperglycemia in trials to date (PMID: 37387074).

Cardiovascular outcomes evidence. Semaglutide has the deepest cardiovascular evidence base in this group. The SUSTAIN-6 trial (NCT01720446) demonstrated a 26% reduction in MACE versus placebo in high-risk type 2 diabetes patients (PMID: 28095528). The SELECT trial (NCT03574597) extended this to a non-diabetic obesity population, showing a 20% reduction in MACE (PMID: 38092489). Tirzepatide has cardiovascular outcomes trials in progress (SURPASS-CVOT, NCT04255433). Retatrutide has no cardiovascular outcomes data beyond Phase II safety signals.

Regulatory maturity. Semaglutide and tirzepatide are both approved by the FDA for type 2 diabetes and obesity, supported by multiple Phase III programs with hundreds of thousands of patient-years of accumulated safety data in clinical trials and post-marketing surveillance. Retatrutide is a Phase III compound with a robust Phase II safety profile but no approval and no long-term outcomes data.

Weight loss magnitude. The progression across these three compounds mirrors the progression in receptor valency. Mean body weight reductions in pivotal obesity trials are approximately 15% for semaglutide, 21% for tirzepatide, and 24% for retatrutide. These figures are from separate trials with different populations, dose escalation schedules, and follow-up durations; direct head-to-head comparison of all three has not been published.

GIP-R agonism: signal or confound. An ongoing scientific debate concerns whether tirzepatide’s GIP-R activity is additive, synergistic, or partially redundant with GLP-1R activation. Mechanistic studies using GIP-R knockout models and selective antagonists support a distinct contribution, but isolating the quantitative contribution in humans is confounded by dual receptor occupancy at clinical doses (PMID: 34170647). Retatrutide’s triple agonism adds a third layer of pharmacological complexity that Phase II data alone cannot fully deconvolute.

Research Outlook and Open Questions

Retatrutide Phase III outcomes. Phase II data for retatrutide (NCT04881760) showed the largest pharmacological weight reduction recorded in a randomized controlled trial, but Phase II programs are typically underpowered for safety signals, rare adverse events, and long-duration efficacy plateaus. Phase III will answer whether the weight loss magnitude is sustained beyond 48 weeks and whether the GCGR component introduces cardiovascular or hepatic risks not apparent in shorter trials.

Muscle mass preservation. A known concern with large-magnitude weight reduction is lean mass loss. Analyses from semaglutide and tirzepatide trials indicate that a meaningful fraction of total weight lost is lean tissue, consistent with pharmacological caloric restriction. Whether triple receptor agonism with GCGR activity worsens or improves this ratio through changes in glucagon-driven protein metabolism is an active research question. Phase III body composition endpoints for retatrutide will be informative. For a focused evidence update, see incretin drugs and lean mass loss.

Non-alcoholic fatty liver disease (NAFLD) and NASH. GLP-1 RAs reduce hepatic steatosis in preclinical and clinical metabolic studies. Dedicated NASH trials for semaglutide (NASH cirrhosis; NCT04822181) and for tirzepatide (SYNERGY-NASH; NCT04166773) are ongoing. The hepatic lipolytic effects of GCGR agonism in retatrutide provide an additional theoretical rationale for liver endpoints, but controlled NASH data for retatrutide have not been published.

Heart failure with preserved ejection fraction (HFpEF). The STEP-HFpEF trial (NCT04788511) reported that semaglutide significantly reduced symptoms, exercise limitation, and body weight in patients with HFpEF and obesity, without a MACE endpoint (PMID: 37632466). Whether the improvement was attributable to weight reduction alone or to direct cardiac GLP-1R signaling remains unresolved. Tirzepatide’s SUMMIT trial (NCT04847557) is evaluating HFpEF outcomes; retatrutide has no dedicated heart failure trials registered. A separate real-world HFrEF signal is summarized in GLP-1 receptor agonists and reduced-ejection-fraction heart failure mortality.

CNS and addiction pathways. GLP-1R is expressed in the mesolimbic dopamine system, and case reports plus retrospective data suggest GLP-1 RAs may reduce cravings for alcohol, nicotine, and other substances. Prospective trials specifically targeting addiction endpoints are in early stages. The CNS distribution of GIP-R and GCGR and their roles in reward signaling are less characterized, making this a particularly open area for the dual and triple agonists.

Durability and weight regain. Controlled cessation studies for semaglutide (STEP 4, NCT03548949) demonstrated that weight regain begins within weeks of discontinuation and approaches the pre-treatment trajectory by 1-2 years. This raises fundamental questions about the duration of therapy required, the biology of weight set-point resetting, and whether any GLP-1 RA produces durable metabolic change independent of continued administration.

Oral formulations. Oral semaglutide (Rybelsus) is approved for type 2 diabetes and is under evaluation for obesity (NCT05035095). The bioavailability of oral peptide formulations remains low (<1% for oral semaglutide without absorption enhancers), driving interest in higher-dose oral formulations and alternative delivery strategies. Oral versions of tirzepatide and retatrutide are in early development.

Compound Hubs

Detailed evidence, mechanism, pharmacokinetics, safety, and dose-response data are organized by compound:

This page is for research and educational purposes. It does not constitute medical advice, dosing guidance, or a recommendation to use any compound. Consult a licensed clinician for individualized guidance.